Daniel Swisher - Jazz Pharmaceuticals President COO
| J7Z Stock | EUR 116.85 1.15 0.97% |
President
Mr. Daniel N. Swisher is the President, Chief Operating Officer of Jazz Pharmaceuticals PLC., effective January 3, 2018. Mr. Swisher was appointed our President and Chief Operating Officer as of January 2018. From December 2003 to December 2017, Mr. Swisher was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporationrationration, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisolmodulating therapeutics to address metabolic and other serious medical conditions since 2018.
| Age | 60 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Daniel Swisher Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Swisher against Jazz Pharmaceuticals stock is an integral part of due diligence when investing in Jazz Pharmaceuticals. Daniel Swisher insider activity provides valuable insight into whether Jazz Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Jazz Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jazz Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Swisher over six months ago Disposition of 2200 shares by Daniel Swisher of Corcept Therapeutics at 5.86 subject to Rule 16b-3 |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Ex RD | ||
| Finbar Larkin, VP Operations | ||
| George Eliades, Sr Officer | ||
| Daniel Swisher, President COO | ||
| Patricia Carr, VP Officer | ||
| Heidi Manna, VP Officer | ||
| Neena JD, Ex Officer | ||
| Renee Gala, Ex CFO | ||
| Andrea Flynn, VP Relations | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.